Acuta Capital Partners buys $16,097,415 stake in Veracyte Inc (VCYT)

Veracyte Inc (VCYT) : Acuta Capital Partners scooped up 450,965 additional shares in Veracyte Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 3,187,607 shares of Veracyte Inc which is valued at $16,097,415.Veracyte Inc makes up approximately 7.88% of Acuta Capital Partners’s portfolio.

Other Hedge Funds, Including , Teachers Advisors Inc reduced its stake in VCYT by selling 2,579 shares or 12.67% in the most recent quarter. The Hedge Fund company now holds 17,773 shares of VCYT which is valued at $89,754.Spot Trading L.l.c reduced its stake in VCYT by selling 1,600 shares or 9.14% in the most recent quarter. The Hedge Fund company now holds 15,900 shares of VCYT which is valued at $78,387. Veracyte Inc makes up approx 0.01% of Spot Trading L.l.c’s portfolio.

Veracyte Inc closed down -0.03 points or -0.53% at $5.6 with 32,389 shares getting traded on Thursday. Post opening the session at $5.63, the shares hit an intraday low of $5.5 and an intraday high of $5.65 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Veracyte Inc reported $-0.40 EPS for the quarter, missing the analyst consensus estimate by $ -0.07 based on the information available during the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.33. The company had revenue of $14.70 million for the quarter, compared to analysts expectations of $14.79 million. The company’s revenue was up 23.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.35 EPS.

Veracyte Inc. is a molecular diagnostics company. The Company is engaged in the field of molecular cytology providing genomic solutions to resolve diagnostic ambiguity and enable physicians to make treatment decisions at an early stage in patient care. It targets diseases in which a large number of patients undergo invasive diagnostic procedures that could be avoided with a diagnosis from a cytology sample. The Company’s commercial solution the Afirma Thyroid FNA Analysis includes as its centerpiece the Gene Expression Classifier (GEC). The GEC allows physicians reduce the number of surgeries by employing a 142-gene signature to pre-operatively determine whether thyroid nodules previously classified by cytopathology as indeterminate can be reclassified as benign. The offering also includes cytopathology testing and the Afirma Malignancy Classifiers. The Company markets and sells Afrma through a co-promotion agreement with Genzyme Corporation a subsidiary of Sanofi.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *